New and updated preclinical and clinical data presented by biopharma firms at the European Society for Medical Oncology Congress 2021, including: Astellas, Astrazeneca, Beyondspring, Byondis, Carsgen, Cstone, Daiichi, Exelixis, Genentech, Genmab, GT, Innovent, Immunocore, Ipsen, Janssen, Merck, Mirati, Novartis, Ose, Regeneron, Sanofi, Spectrum, Verastem, Veru.
Despite Beyondspring Pharmaceuticals Inc.’s phase III study meeting its primary and key secondary endpoints of a plinabulin/docetaxel combination in treating non-small-cell lung cancer (NSCLC), the company stock (NADAQ:BYSI) took a pounding. Shares sunk 32.9% on Sept. 20 to close at $15.36 each.
Takeda Pharmaceutical Co. Ltd. has grabbed a slice of the non-small-cell lung cancer (NSCLC) market, becoming the first company to gain FDA approval for an oral drug targeted against a rare form of the disease.
Although targeted therapies are prescribed on the basis of a patient's molecular makeup, they do not work every time. And in those instances where they do work, they basically stop working every time. In response, researchers have developed a number of systems whose goal it is to predict which drugs will be effective for an individual patients.
RSS
